The symposium programme is a chance to hear the latest thinking and evidence about healthy approaches to drug law from around the world and within Aotearoa New Zealand. Our guest speakers will offer insights to fuel debate about on how New Zealand can develop drug laws that are fit for the 21st Century.
More details are being added as speakers confirm. This provisional agenda was last updated on 12 June 2017.
Welcome from Alison Mau, symposium chair
Opening address by Hon Peter Dunne, Associate Minister of Health
Professor Alison Ritter (Australia), Director, Drug Policy Modelling Program, National Drug and Alcohol Research Centre, University of New South Wales
The case of Canada – Hon A. Anne McLellan (Canada), Chancellor Dalhousie University, Chair, Task Force on Cannabis Legalization and Regulation; former Deputy Prime Minister, Canada
The case of Washington State, and wider US reform – Alison Holcomb (USA), Author and Campaign Director, Washington State Cannabis Legalisation Law
Political panel – reflections on keynote addresses
Discussion and questions from the floor:
Ann Fordham (UK), Executive Director, International Drug Policy Consortium
Professor Nicole Lee (Australia) National Drug Research Institute, Curtin University; Director, 360Edge
* Speaker to be confirmed.
Professor Khylee Quince, Associate Head of School, Director of Maori and Pacific Advancement, AUT School of Law; Trustee, NZ Drug Foundation
Professor Tracey McIntosh, Professor of Indigenous Studies and Co-Head of Te Wānanga o Waipapa
Alison Holcomb, Author and Campaign Director, Washington State Cannabis Legalisation Law
Dr Marianne Jauncey (Australia), Director, Uniting Medically Supervised Injecting Centre, Sydney
Respondent: Kathryn Leafe, Executive Director, New Zealand Needle Exchange Programme
Professor Fiona Measham (UK), Criminology, School of Applied Social Sciences, Durham University; Member, Advisory Council on the Misuse of Drugs; Co-Director, The Loop, UK
Respondent: Wendy Allison, Director, Know Your Stuff
Professor Nicole Lee (Austraila), Adjunct Professor, National Drug Research Institute, Curtin University; Director, 360Edge
Respondent: Dr Vanessa Caldwell, National Manager, Matua Raki
A chance for final thoughts comments
Survey participants also reported that barriers to accessing services, resources and information were high.
A group of powerful synthetic opioids that were first detected in the country just a year ago may have already been linked to several deaths.
95% of respondents reported positive effects, in a study that looked at both prescription and black market cannabis use.